MS
Venture Partner
Jacob M. Rayyan brings a strong scientific and analytical foundation to early-stage healthcare investing, with experience spanning biotech R&D, scientific analysis, and venture evaluation. He has sourced, assessed, and conducted due diligence on therapeutics companies across oncology, neuroengineering, and gene therapy. His expertise includes investment strategy, financial modeling, LP engagement, and the evaluation of preclinical and clinical data to identify high-potential opportunities. Jacob holds an MS in Neurobiology from Northwestern University and a BS in Biomedical Engineering from Case Western Reserve University.
Jacob’s motivation to join GHIF is rooted in his commitment to advancing innovation in oncology and life sciences. Having worked at the intersection of scientific discovery, clinical development, and venture capital, he is driven by the opportunity to support founders translating breakthrough research into meaningful therapies. GHIF’s mission aligns closely with his dedication to improving patient outcomes by backing technologies that move the needle in cancer care and beyond.
With his combined training in neurobiology, biomedical engineering, and scientific due diligence, Jacob brings a rigorous, research-driven lens to venture investing. At GHIF, he leverages his strengths in evaluating data, engaging key opinion leaders, and developing clear, evidence-based investment theses. He is particularly focused on helping the fund identify and support groundbreaking ventures in oncology, ensuring that transformational science is matched with strategic capital and expert guidance.